A post-ganglionic sympathetic blocker
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Debrisoquin (hemisulfate)

Item No. 29568

Technical Information
Formal Name
3,4-dihydro-2(1H)-isoquinolinecarboximidamide, hemisulfate
CAS Number
581-88-4
Synonyms
  • Isocaramidine sulfate
  • Ro 5-3307/1
Molecular Formula
C10H13N3 • 1/2H2SO4
Formula Weight
Purity
≥98%
A crystalline solid
PBS (pH 7.2): 1 mg/ml
SMILES
NC(N1CCC2=CC=CC=C2C1)=N.O=S(O)(O)=O
InChi Code
InChI=1S/2C10H13N3.H2O4S/c2*11-10(12)13-6-5-8-3-1-2-4-9(8)7-13;1-5(2,3)4/h2*1-4H,5-7H2,(H3,11,12);(H2,1,2,3,4)
InChi Key
CAYGYVYWRIHZCQ-UHFFFAOYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Add

    Add

    Product Description

    Debrisoquin is a post-ganglionic sympathetic blocker.1 It increases accumulation of the monoamine oxidase (MAO) substrate l-m-octopamine in isolated rabbit heart when used at a concentration of 1 mM.2 Debrisoquin reduces norepinephrine levels in the left and right atrium and ventricles, as well as the mesenteric and femoral arteries in anesthetized dogs when administered at a dose of 5 mg/kg per day for seven days.3 Debrisoquin decreases mean aortic pressure, heart rate, and total peripheral vascular resistance in the same model.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Heffernan, A.G.A., and Carty, A.T. Clinical observations on the use of debrisoquine sulphate (declinax) in the treatment of hypertension. I. J. Med. Sc. 3(1), 37-43 (1970).

    2. Giachetti, A., and Shore, P.A. Monoamine oxidase inhibition in the adrenergic neuron by bretylium, debrisoquin, and other adrenergic neuronal blocking agents. Biochem. Pharmacol. 16, 237-238 (1966).

    3. Cavero, I., Gerold, M., Saner, A., et alThe cardiovascular effects of the antihypertensive drug debrisoquin: A contribution to the pharmacology of chronic treatment. I. one-week administration to dogs. J. Pharmacol. Exp. Ther. 206(1), 123-131 (1978).